Last Friday the IPKat had a little moan about the lack of IP decisions by female IP judges. Then, as if by magic, in today's Court of Appeal decision in IN Newman (blogged below) Lady Justice Arden delivered a partially dissenting judgment.

Passionate about IP! Since June 2003 the IPKat weblog has covered copyright, patent, trade mark, info-tech and privacy/confidentiality issues from a mainly UK and European perspective. The team is David Brophy, Merpel, Jeremy Phillips, Eleonora Rosati, Darren Smyth, Annsley Merelle Ward and Neil J. Wilkof. You're welcome to read, post comments and participate in our community. You can email the Kats here
Last Friday the IPKat had a little moan about the lack of IP decisions by female IP judges. Then, as if by magic, in today's Court of Appeal decision in IN Newman (blogged below) Lady Justice Arden delivered a partially dissenting judgment.

* Listed as a "Top Legal Blog" in The Times Online, March 2011
* One of only two non-US weblogs listed in the 2010 ABA Journal Blawg 100
* Court Reporter Top Copyright Blog award winner, November 2010
* Number 1 in the 2010 Top Copyright Blog list compiled by the Copyright Litigation Blog, July 2010
* Selected by United States Library of Congress for inclusion in its historic collections of Internet materials related to Legal Blawgs 2010
* Top Patent Blog poll 2009: 3rd out of 50 in the "Favourite Patent Blog" poll and 2nd out of 50 in the "Most-read" poll
* ComputerWeekly IT Law and Governance Blog of the Year 20 August 2008
* Best of the Blogs, Times Online, 21 August 2008
* Listed as one of Managing Intellectual Property magazine's Fifty Most Influential People of 2005 and again in 2011
2 comments:
No disrespect to Lady Justice Arden, who is certainly both a lady and a fine judge -- but I don't think she counts as an IP judge.
Nor soon will our friend Sir Hugh, who is a Laddie but will not, alas ("a lass") be an IP judge much longer.
One also cannot help but notice that Lady Justice Arden appears to dissent in her IP-related judgements: see this case and the Celltech/Medimmune case.
Post a Comment